Entecavir	B:C0971023
to	O
Telbivudine	O
Switch	O
Therapy	O
in	O
Entecavir	O
-	O
Treated	O
Patients	O
with	O
Undetectable	O
Hepatitis	O
B	O
Viral	O
DNA	O
.	O

Entecavir	O
to	O
Telbivudine	B:C1453933
Switch	O
Therapy	O
in	O
Entecavir	O
-	O
Treated	O
Patients	O
with	O
Undetectable	O
Hepatitis	O
B	O
Viral	O
DNA	O
.	O

Entecavir	O
to	O
Telbivudine	O
Switch	B:C2936279
Therapy	O
in	O
Entecavir	O
-	O
Treated	O
Patients	O
with	O
Undetectable	O
Hepatitis	O
B	O
Viral	O
DNA	O
.	O

Entecavir	O
to	O
Telbivudine	O
Switch	O
Therapy	B:C0087111
in	O
Entecavir	O
-	O
Treated	O
Patients	O
with	O
Undetectable	O
Hepatitis	O
B	O
Viral	O
DNA	O
.	O

Entecavir	O
to	O
Telbivudine	O
Switch	O
Therapy	O
in	O
Entecavir	B:C0971023
-	O
Treated	O
Patients	O
with	O
Undetectable	O
Hepatitis	O
B	O
Viral	O
DNA	O
.	O

Entecavir	O
to	O
Telbivudine	O
Switch	O
Therapy	O
in	O
Entecavir	O
-	O
Treated	O
Patients	O
with	O
Undetectable	B:C3827727
Hepatitis	O
B	O
Viral	O
DNA	O
.	O

This	O
study	O
examined	O
2	O
-	O
year	O
outcome	O
of	O
consecutive	O
therapy	B:C0087111
using	O
entecavir	O
(	O
entecavir	O
)	O
followed	O
by	O
telbivudine	O
(	O
LdT	O
)	O
in	O
subjects	O
with	O
undetectable	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
level	O
and	O
normal	O
alanine	O
aminotransferase	I:C0201836
level	I:C0201836
after	O
the	O
initial	O
6	O
months	O
of	O
entecavir	O
treatment	O
.	O

This	O
study	O
examined	O
2	O
-	O
year	O
outcome	O
of	O
consecutive	O
therapy	O
using	O
entecavir	B:C0971023
(	O
entecavir	O
)	O
followed	O
by	O
telbivudine	O
(	O
LdT	O
)	O
in	O
subjects	O
with	O
undetectable	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
level	O
and	O
normal	O
alanine	O
aminotransferase	I:C0201836
level	I:C0201836
after	O
the	O
initial	O
6	O
months	O
of	O
entecavir	O
treatment	O
.	O

This	O
study	O
examined	O
2	O
-	O
year	O
outcome	O
of	O
consecutive	O
therapy	O
using	O
entecavir	O
(	O
entecavir	B:C0971023
)	O
followed	O
by	O
telbivudine	O
(	O
LdT	O
)	O
in	O
subjects	O
with	O
undetectable	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
level	O
and	O
normal	O
alanine	O
aminotransferase	I:C0201836
level	I:C0201836
after	O
the	O
initial	O
6	O
months	O
of	O
entecavir	O
treatment	O
.	O

This	O
study	O
examined	O
2	O
-	O
year	O
outcome	O
of	O
consecutive	O
therapy	O
using	O
entecavir	O
(	O
entecavir	O
)	O
followed	O
by	O
telbivudine	B:C1453933
(	O
LdT	O
)	O
in	O
subjects	O
with	O
undetectable	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
level	O
and	O
normal	O
alanine	O
aminotransferase	I:C0201836
level	I:C0201836
after	O
the	O
initial	O
6	O
months	O
of	O
entecavir	O
treatment	O
.	O

This	O
study	O
examined	O
2	O
-	O
year	O
outcome	O
of	O
consecutive	O
therapy	O
using	O
entecavir	O
(	O
entecavir	O
)	O
followed	O
by	O
telbivudine	O
(	O
LdT	B:C1453933
)	O
in	O
subjects	O
with	O
undetectable	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
level	O
and	O
normal	O
alanine	O
aminotransferase	I:C0201836
level	I:C0201836
after	O
the	O
initial	O
6	O
months	O
of	O
entecavir	O
treatment	O
.	O

This	O
study	O
examined	O
2	O
-	O
year	O
outcome	O
of	O
consecutive	O
therapy	O
using	O
entecavir	O
(	O
entecavir	O
)	O
followed	O
by	O
telbivudine	O
(	O
LdT	O
)	O
in	O
subjects	B:C0080105
with	O
undetectable	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
level	O
and	O
normal	O
alanine	O
aminotransferase	I:C0201836
level	I:C0201836
after	O
the	O
initial	O
6	O
months	O
of	O
entecavir	O
treatment	O
.	O

This	O
study	O
examined	O
2	O
-	O
year	O
outcome	O
of	O
consecutive	O
therapy	O
using	O
entecavir	O
(	O
entecavir	O
)	O
followed	O
by	O
telbivudine	O
(	O
LdT	O
)	O
in	O
subjects	O
with	O
undetectable	B:C3827727
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
level	O
and	O
normal	O
alanine	O
aminotransferase	I:C0201836
level	I:C0201836
after	O
the	O
initial	O
6	O
months	O
of	O
entecavir	O
treatment	O
.	O

This	O
study	O
examined	O
2	O
-	O
year	O
outcome	O
of	O
consecutive	O
therapy	O
using	O
entecavir	O
(	O
entecavir	O
)	O
followed	O
by	O
telbivudine	O
(	O
LdT	O
)	O
in	O
subjects	O
with	O
undetectable	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
level	O
and	O
normal	O
alanine	B:C0201836
aminotransferase	I:C0201836
level	I:C0201836
after	O
the	O
initial	O
6	O
months	O
of	O
entecavir	O
treatment	O
.	O

This	O
study	O
examined	O
2	O
-	O
year	O
outcome	O
of	O
consecutive	O
therapy	O
using	O
entecavir	O
(	O
entecavir	O
)	O
followed	O
by	O
telbivudine	O
(	O
LdT	O
)	O
in	O
subjects	O
with	O
undetectable	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
level	O
and	O
normal	O
alanine	O
aminotransferase	I:C0201836
level	I:C0201836
after	O
the	O
initial	O
6	O
months	O
of	O
entecavir	B:C0971023
treatment	O
.	O

This	O
study	O
examined	O
2	O
-	O
year	O
outcome	O
of	O
consecutive	O
therapy	O
using	O
entecavir	O
(	O
entecavir	O
)	O
followed	O
by	O
telbivudine	O
(	O
LdT	O
)	O
in	O
subjects	O
with	O
undetectable	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
level	O
and	O
normal	O
alanine	O
aminotransferase	I:C0201836
level	I:C0201836
after	O
the	O
initial	O
6	O
months	O
of	O
entecavir	O
treatment	B:C0087111
.	O

Sixty	O
subjects	B:C0080105
were	O
randomized	O
to	O
continue	O
with	O
entecavir	O
or	O
switch	O
to	O
LdT	O
.	O

Sixty	O
subjects	O
were	O
randomized	O
to	O
continue	O
with	O
entecavir	B:C0971023
or	O
switch	O
to	O
LdT	O
.	O

Sixty	O
subjects	O
were	O
randomized	O
to	O
continue	O
with	O
entecavir	O
or	O
switch	B:C2936279
to	O
LdT	O
.	O

Sixty	O
subjects	O
were	O
randomized	O
to	O
continue	O
with	O
entecavir	O
or	O
switch	O
to	O
LdT	B:C1453933
.	O

Significant	O
difference	O
in	O
baseline	B:C1290922
characteristics	I:C1290922
was	O
not	O
found	O
between	O
the	O
two	O
groups	O
.	O

During	O
96	O
weeks	O
of	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
,	O
all	O
subjects	O
of	O
the	O
entecavir	O
-	O
only	O
group	O
(	O
n=30	O
)	O
resulted	O
in	O
undetectable	O
HBV	O
DNA	O
level	O
.	O

During	O
96	O
weeks	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
all	O
subjects	B:C0080105
of	O
the	O
entecavir	O
-	O
only	O
group	O
(	O
n=30	O
)	O
resulted	O
in	O
undetectable	O
HBV	O
DNA	O
level	O
.	O

During	O
96	O
weeks	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
all	O
subjects	O
of	O
the	O
entecavir	B:C0971023
-	O
only	O
group	O
(	O
n=30	O
)	O
resulted	O
in	O
undetectable	O
HBV	O
DNA	O
level	O
.	O

During	O
96	O
weeks	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
all	O
subjects	O
of	O
the	O
entecavir	O
-	O
only	O
group	O
(	O
n=30	O
)	O
resulted	O
in	O
undetectable	B:C3827727
HBV	O
DNA	O
level	O
.	O

On	O
the	O
other	O
hand	O
,	O
83.3	O
%	O
(	O
n=25	O
)	O
of	O
the	O
LdT	B:C1453933
-	O
switched	O
group	O
showed	O
treatment	O
success	O
.	O

On	O
the	O
other	O
hand	O
,	O
83.3	O
%	O
(	O
n=25	O
)	O
of	O
the	O
LdT	O
-	O
switched	B:C2936279
group	O
showed	O
treatment	O
success	O
.	O

Virological	O
rebound	B:C0549262
time	O
varied	O
from	O
week	O
24	O
to	O
84	O
after	O
switching	O
to	O
LdT.	O

Virological	O
rebound	O
time	O
varied	O
from	O
week	O
24	O
to	O
84	O
after	O
switching	B:C2936279
to	O
LdT.	O

Virological	O
rebound	O
time	O
varied	O
from	O
week	O
24	O
to	O
84	O
after	O
switching	O
to	O
LdT.	B:C1453933

HBV	O
DNA	O
level	O
was	O
180	O
to	O
2940	O
IU	O
/	O
mL	O
at	O
rebound	B:C0549262
time	O
.	O

All	O
subjects	B:C0080105
with	O
virological	O
rebound	O
(	O
n=5	O
)	O
showed	O
drug	O
-	I:C0013203
resistant	I:C0013203
mutation	O
:	O
three	O
had	O
mutation	O
rtM204I	O
,	O
and	O
two	O
had	O
mutation	O
rtM204V	O
.	O

All	O
subjects	O
with	O
virological	O
rebound	B:C0549262
(	O
n=5	O
)	O
showed	O
drug	O
-	I:C0013203
resistant	I:C0013203
mutation	O
:	O
three	O
had	O
mutation	O
rtM204I	O
,	O
and	O
two	O
had	O
mutation	O
rtM204V	O
.	O

All	O
subjects	O
with	O
virological	O
rebound	O
(	O
n=5	O
)	O
showed	O
drug	B:C0013203
-	I:C0013203
resistant	I:C0013203
mutation	O
:	O
three	O
had	O
mutation	O
rtM204I	O
,	O
and	O
two	O
had	O
mutation	O
rtM204V	O
.	O

All	O
subjects	O
with	O
virological	O
rebound	O
(	O
n=5	O
)	O
showed	O
drug	O
-	I:C0013203
resistant	I:C0013203
mutation	B:C0596611
:	O
three	O
had	O
mutation	O
rtM204I	O
,	O
and	O
two	O
had	O
mutation	O
rtM204V	O
.	O

All	O
subjects	O
with	O
virological	O
rebound	O
(	O
n=5	O
)	O
showed	O
drug	O
-	I:C0013203
resistant	I:C0013203
mutation	O
:	O
three	O
had	O
mutation	B:C0596611
rtM204I	O
,	O
and	O
two	O
had	O
mutation	O
rtM204V	O
.	O

All	O
subjects	O
with	O
virological	O
rebound	O
(	O
n=5	O
)	O
showed	O
drug	O
-	I:C0013203
resistant	I:C0013203
mutation	O
:	O
three	O
had	O
mutation	O
rtM204I	B:C1335440
,	O
and	O
two	O
had	O
mutation	O
rtM204V	O
.	O

All	O
subjects	O
with	O
virological	O
rebound	O
(	O
n=5	O
)	O
showed	O
drug	O
-	I:C0013203
resistant	I:C0013203
mutation	O
:	O
three	O
had	O
mutation	O
rtM204I	O
,	O
and	O
two	O
had	O
mutation	B:C0596611
rtM204V	O
.	O

All	O
subjects	O
with	O
virological	O
rebound	O
(	O
n=5	O
)	O
showed	O
drug	O
-	I:C0013203
resistant	I:C0013203
mutation	O
:	O
three	O
had	O
mutation	O
rtM204I	O
,	O
and	O
two	O
had	O
mutation	O
rtM204V	B:C1335440
.	O

Consecutive	O
treatment	B:C0087111
using	O
entecavir	O
followed	O
by	O
LdT	O
showed	O
virological	O
rebound	O
in	O
16.7	O
%	O
of	O
subjects	O
during	O
96	O
weeks	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Consecutive	O
treatment	O
using	O
entecavir	B:C0971023
followed	O
by	O
LdT	O
showed	O
virological	O
rebound	O
in	O
16.7	O
%	O
of	O
subjects	O
during	O
96	O
weeks	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Consecutive	O
treatment	O
using	O
entecavir	O
followed	O
by	O
LdT	B:C1453933
showed	O
virological	O
rebound	O
in	O
16.7	O
%	O
of	O
subjects	O
during	O
96	O
weeks	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Consecutive	O
treatment	O
using	O
entecavir	O
followed	O
by	O
LdT	O
showed	O
virological	O
rebound	B:C0549262
in	O
16.7	O
%	O
of	O
subjects	O
during	O
96	O
weeks	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Consecutive	O
treatment	O
using	O
entecavir	O
followed	O
by	O
LdT	O
showed	O
virological	O
rebound	O
in	O
16.7	O
%	O
of	O
subjects	B:C0080105
during	O
96	O
weeks	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Consecutive	O
treatment	O
using	O
entecavir	O
followed	O
by	O
LdT	O
showed	O
virological	O
rebound	O
in	O
16.7	O
%	O
of	O
subjects	O
during	O
96	O
weeks	O
of	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
.	O

HBV	O
DNA	O
negativity	B:C1513916
during	O
initial	O
entecavir	O
therapy	O
could	O
not	O
be	O
achieved	O
in	O
patients	O
who	O
switched	O
to	O
LdT	O
.	O

HBV	O
DNA	O
negativity	O
during	O
initial	O
entecavir	B:C0971023
therapy	O
could	O
not	O
be	O
achieved	O
in	O
patients	O
who	O
switched	O
to	O
LdT	O
.	O

HBV	O
DNA	O
negativity	O
during	O
initial	O
entecavir	O
therapy	B:C0087111
could	O
not	O
be	O
achieved	O
in	O
patients	O
who	O
switched	O
to	O
LdT	O
.	O

HBV	O
DNA	O
negativity	O
during	O
initial	O
entecavir	O
therapy	O
could	O
not	O
be	O
achieved	O
in	O
patients	O
who	O
switched	B:C2936279
to	O
LdT	O
.	O

HBV	O
DNA	O
negativity	O
during	O
initial	O
entecavir	O
therapy	O
could	O
not	O
be	O
achieved	O
in	O
patients	O
who	O
switched	O
to	O
LdT	B:C1453933
.	O

Consecutive	O
treatment	B:C0087111
using	O
entecavir	O
followed	O
by	O
lamivudine	O
was	O
ineffective	O
for	O
treating	O
chronic	O
hepatitis	I:C0524909
B.	I:C0524909
LdT	O
was	O
found	O
as	O
a	O
more	O
potent	O
antiviral	O
agent	I:C0003451
than	O
lamivudine	O
.	O

Consecutive	O
treatment	O
using	O
entecavir	B:C0971023
followed	O
by	O
lamivudine	O
was	O
ineffective	O
for	O
treating	O
chronic	O
hepatitis	I:C0524909
B.	I:C0524909
LdT	O
was	O
found	O
as	O
a	O
more	O
potent	O
antiviral	O
agent	I:C0003451
than	O
lamivudine	O
.	O

Consecutive	O
treatment	O
using	O
entecavir	O
followed	O
by	O
lamivudine	B:C0209738
was	O
ineffective	O
for	O
treating	O
chronic	O
hepatitis	I:C0524909
B.	I:C0524909
LdT	O
was	O
found	O
as	O
a	O
more	O
potent	O
antiviral	O
agent	I:C0003451
than	O
lamivudine	O
.	O

Consecutive	O
treatment	O
using	O
entecavir	O
followed	O
by	O
lamivudine	O
was	O
ineffective	O
for	O
treating	B:C0087111
chronic	O
hepatitis	I:C0524909
B.	I:C0524909
LdT	O
was	O
found	O
as	O
a	O
more	O
potent	O
antiviral	O
agent	I:C0003451
than	O
lamivudine	O
.	O

Consecutive	O
treatment	O
using	O
entecavir	O
followed	O
by	O
lamivudine	O
was	O
ineffective	O
for	O
treating	O
chronic	B:C0524909
hepatitis	I:C0524909
B.	I:C0524909
LdT	O
was	O
found	O
as	O
a	O
more	O
potent	O
antiviral	O
agent	I:C0003451
than	O
lamivudine	O
.	O

Consecutive	O
treatment	O
using	O
entecavir	O
followed	O
by	O
lamivudine	O
was	O
ineffective	O
for	O
treating	O
chronic	O
hepatitis	I:C0524909
B.	I:C0524909
LdT	B:C1453933
was	O
found	O
as	O
a	O
more	O
potent	O
antiviral	O
agent	I:C0003451
than	O
lamivudine	O
.	O

Consecutive	O
treatment	O
using	O
entecavir	O
followed	O
by	O
lamivudine	O
was	O
ineffective	O
for	O
treating	O
chronic	O
hepatitis	I:C0524909
B.	I:C0524909
LdT	O
was	O
found	O
as	O
a	O
more	O
potent	O
antiviral	B:C0003451
agent	I:C0003451
than	O
lamivudine	O
.	O

Consecutive	O
treatment	O
using	O
entecavir	O
followed	O
by	O
lamivudine	O
was	O
ineffective	O
for	O
treating	O
chronic	O
hepatitis	I:C0524909
B.	I:C0524909
LdT	O
was	O
found	O
as	O
a	O
more	O
potent	O
antiviral	O
agent	I:C0003451
than	O
lamivudine	B:C0209738
.	O

However	O
,	O
this	O
conclusion	O
requires	O
larger	O
-	O
scale	O
,	O
long	O
-	O
term	O
prospective	B:C0033522
reviews	I:C0033522
of	O
the	O
treatment	O
effects	O
of	O
entecavir	O
-	O
LdT	O
switch	O
therapy	O
.	O

However	O
,	O
this	O
conclusion	O
requires	O
larger	O
-	O
scale	O
,	O
long	O
-	O
term	O
prospective	O
reviews	I:C0033522
of	O
the	O
treatment	B:C0087111
effects	O
of	O
entecavir	O
-	O
LdT	O
switch	O
therapy	O
.	O

However	O
,	O
this	O
conclusion	O
requires	O
larger	O
-	O
scale	O
,	O
long	O
-	O
term	O
prospective	O
reviews	I:C0033522
of	O
the	O
treatment	O
effects	O
of	O
entecavir	B:C0971023
-	O
LdT	O
switch	O
therapy	O
.	O

However	O
,	O
this	O
conclusion	O
requires	O
larger	O
-	O
scale	O
,	O
long	O
-	O
term	O
prospective	O
reviews	I:C0033522
of	O
the	O
treatment	O
effects	O
of	O
entecavir	O
-	O
LdT	B:C1453933
switch	O
therapy	O
.	O

However	O
,	O
this	O
conclusion	O
requires	O
larger	O
-	O
scale	O
,	O
long	O
-	O
term	O
prospective	O
reviews	I:C0033522
of	O
the	O
treatment	O
effects	O
of	O
entecavir	O
-	O
LdT	O
switch	B:C2936279
therapy	O
.	O

However	O
,	O
this	O
conclusion	O
requires	O
larger	O
-	O
scale	O
,	O
long	O
-	O
term	O
prospective	O
reviews	I:C0033522
of	O
the	O
treatment	O
effects	O
of	O
entecavir	O
-	O
LdT	O
switch	O
therapy	B:C0087111
.	O

